Novavax (NVAX) Cash & Equivalents (2010 - 2026)

Novavax's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $228.4 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 2038.03% year-over-year to $228.4 million in Q1 2026; TTM through Mar 2026 was $228.4 million, a 2038.03% increase from a year earlier, with the FY2025 full-year figure at $10.9 million, up 2.35% from the prior year.
• Cash & Equivalents advanced to $228.4 million in Q1 2026 per NVAX's latest filing, from $10.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.6 billion in Q1 2022 and bottomed at $10.3 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $253.7 million (2025), against an average of $341.2 million.
• Across the five-year window, Cash & Equivalents slumped 99.5% in 2022 and surged 5937.13% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $10.3 million in 2022, then surged by 5417.86% to $568.5 million in 2023, then plunged by 98.13% to $10.6 million in 2024, then advanced by 2.35% to $10.9 million in 2025, then jumped by 1999.7% to $228.4 million in 2026.
• Per Business Quant, the three latest NVAX Cash & Equivalents figures stand at $228.4 million (Q1 2026), $10.9 million (Q4 2025), and $268.0 million (Q3 2025).